Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,678.65
(
-0.56%
)
US TECH 100
24,051.20
(
-0.34%
)
Dow Jones
46,595.76
(
-0.85%
)
Brent Oil
105.79
(
5.11%
)
Bitcoin
71,240.41
(
-3.65%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 76302

Tuesday, 06/30/2009 10:35:11 AM

Tuesday, June 30, 2009 10:35:11 AM

Post# of 257253
Biolex completes enrollment of phase 2b Locteron trial in HCV:

http://finance.yahoo.com/news/Biolex-Therapeutics-Announces-iw-2990286556.html

It took Biolex only two months to enroll 100 patients, which is quite impressive. This trial will continue for another two years or so; however, as mentioned in #msg-37178496, Biolex plans to start phase-3 while the phase-2b trial is still running. The viral-load data at 12 weeks will be used to select the dose(s) to be tested in phase-3.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now